Received May 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TDAP | TDAP (BOOSTRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | cx4hl | — |
Administration in 19 month old; Use Boostrix as the 4th dose in Dtap series/accidentally received dose of Boostrix; This non-serious case was reported by a other health professional via call center representative and described the occurrence of inappropriate age at vaccine administration in a 19-month-old male patient who received DTPa (Reduced antigen) (Boostrix) (batch number cx4hl, expiry date 19-JAN-2026) for prophylaxis. Previously administered products included DTaP (received first 3 doses). On 22-MAY-2025, the patient received the 1st dose of Boostrix. On 22-MAY-2025, an unknown time after receiving Boostrix, the patient experienced inappropriate age at vaccine administration (Verbatim: Administration in 19 month old) and wrong vaccine administered (Verbatim: Use Boostrix as the 4th dose in Dtap series/accidentally received dose of Boostrix). The outcome of the inappropriate age at vaccine administration and wrong vaccine administered were not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 23-MAY-2025 Healthcare professional called in to report that a 19 month old patient initially received their first 3 doses as DTaP and accidentally received a dose of Boostrix, which led wrong vaccine administered and inappropriate age at vaccine administration. The reporter did not consent to follow-up.